Therapeutic Asset Ratings
209 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[177lu]lu-nns309
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P1
C
(36)
[225ac]-fpi-2068
Non-Small Cell Lung Carcinoma
AstraZeneca
P1
C
(36)
[68Ga]Ga-NNS309
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P1
C
(36)
Amg 160
Non-Small Cell Lung Carcinoma
Amgen
P1
C
(36)
asp1893
Non-Small Cell Lung Carcinoma
Astellas Pharma Global Development, Inc.
P1
C
(36)
Autologous, Engineered T Cells Targeting Tp53 R175H
Non-Small Cell Lung Carcinoma
AstraZeneca
P1
C
(36)
AZD0240
Non-Small Cell Lung Carcinoma
AstraZeneca
P1
C
(36)
azd0240: autologous, engineered t cells targeting kras g12d
Non-Small Cell Lung Carcinoma
AstraZeneca
P1
C
(36)
Bbo-8520
Non-Small Cell Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
P1
C
(36)
Bdc-3042
Non-Small Cell Lung Carcinoma
Bolt Biotherapeutics, Inc.
P1
C
(36)
Bexmarilimab
Non-Small Cell Lung Carcinoma
The University of Texas Health Science Center at San Antonio
P1
C
(36)
Bgb-43395
Non-Small Cell Lung Carcinoma
BeOne Medicines
P1
C
(36)
Bl-M09D1
Non-Small Cell Lung Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
bmc128
Non-Small Cell Lung Carcinoma
Biomica Ltd.
P1
C
(36)
BMS986310
Non-Small Cell Lung Carcinoma
Ono Pharmaceutical Co., Ltd.
P1
C
(36)
Bpi-442096
Non-Small Cell Lung Carcinoma
Betta Pharmaceuticals Co., Ltd.
P1
C
(36)
CRX100
Non-Small Cell Lung Carcinoma
BioEclipse Therapeutics
P1
C
(36)
do-2
Non-Small Cell Lung Carcinoma
DeuterOncology
P1
C
(36)
Drug: Ibi3028
Non-Small Cell Lung Carcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P1
C
(36)
Elacestrant
Non-Small Cell Lung Carcinoma
BeOne Medicines
P1
C
(36)
Exarafenib
Non-Small Cell Lung Carcinoma
Pierre Fabre Medicament
P1
C
(36)
Gnc-077
Non-Small Cell Lung Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
hh160
Non-Small Cell Lung Carcinoma
Huahui Health
P1
C
(36)
imm2520
Non-Small Cell Lung Carcinoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
P1
C
(36)
Interleukin-12 Gene
Non-Small Cell Lung Carcinoma
The Methodist Hospital Research Institute
P1
C
(36)
Showing 151 to 175 of 209 assets
Previous
Page 7 of 9
Next